Background: We hypothesized that common breast cancer risk alleles are associated with incidences of breast cancer and other cancers in the general population, and identify low risk women among those invited for screening mammography.
Introduction
The idea of using common low-penetrance alleles to predict breast cancer risk has been discussed [1] [2] [3] , since personalized versus age-based screening could potentially reduce the number of women eligible for screening, while at the same time detect more breast cancers [4, 5] .
Risk of breast cancer by common breast cancer risk alleles has recently been examined in a large study [6] . That study largely used case/control studies with the same individuals as were used to discover many of the variants, and validated results in an independent case/control study. However, before any future implementation of routine measurement of common breast cancer risk alleles, several questions must be answered. First, does such a test predict breast cancer risk in the general population? Second, does it predict risk of breast cancers with possible impact on life-expectancy, and not only relatively indolent tumors, which would not have been discovered, had the woman not had mammography? This is important since we ultimately want to reduce breast cancer mortality, and not only detect breast cancers. Third, does it predict risk of other cancers than breast cancer? This is unknown, but important since such a test potentially could be offered to most women. Furthermore, since the exact mechanistic role of only very few of the breast cancer risk loci is known, it is plausible that some loci are involved in several cell pathways shared by many cancers. Fourth, how does it interact with conventional risk factors for breast cancer?
In order to address these questions, we mainly used the sum of alleles previously reported to be associated with increased risk of breast cancer, and not the more conventional polygenic risk score, ie. the product of all breast cancer alleles and their reported individual breast cancer odds ratios according to previous studies. Apart from being intuitively understandable as a simple sum, we speculated that the breast cancer allele sum rather than the polygenic risk score would be more sensitive in detecting associations with other endpoints (breast cancer mortality and other cancers), than the one (breast cancer) used to identify the loci. Also, since the loci were typically identified together with its inferred risk increase in the same study, and therefore not independently determined, we assume that the simple sum would represent a conservative approach, when evaluating breast cancer risk.
We hypothesized that breast cancer allele sum was associated with increased breast cancer incidence and mortality, and with incidence of other cancers in the general population. Interactions with conventional risk factors were measured. We also constructed 5-year absolute breast cancer incidence estimates in women as a function of age, nulliparity, familial breast cancer, and breast cancer allele sum for 72 breast cancer susceptibility loci, and determined the proportion of women currently offered screening mammography with a risk below the cutoff of average risk for a 50-year-old woman from this study.
Methods

Settings and individuals
We studied 35 441 individuals from the 1991-1994 examination of the Copenhagen City Heart Study [7] and the Copenhagen General Population Study [8] . Examination procedures and covariates obtained at examination are described in detail in the online Supplementary material.
Endpoints
Cancer diagnoses, cause and date of death were from the Danish health registries, described in detail in the online Supplementary material.
Genotyping
We genotyped individuals for 72 loci found in previous genome-wide association studies to be independently associated with breast cancer risk, and known at the time the project was initiated (supplementary Table S1 and online Supplementary material, available at Annals of Oncology online) [6, 9] .
Statistical analyses
We used STATA 13.1 SE to perform the statistical analyses. Details are described in the online Supplementary material.
Results
The breast cancer allele sum was normal distributed (supplemen tary Figure S1 , available at Annals of Oncology online). There were no major differences across the quintiles of breast cancer allele sum for any of the characteristics recorded at the day of examination, although there were as expected slightly more first-degree relatives with breast cancer among the higher quintiles (supplementary Table S2 , available at Annals of Oncology online).
Cancer incidence
Of the 35 441 individuals, 1301 women developed breast cancer and 4972 women and men developed other cancers. The cumulative incidence for breast cancer in women increased by breast cancer allele sum quintiles (log-rank trend test; P ¼ 1Â10 À 12 ), but not for other cancers in women (P ¼ 0.41) and men (P ¼ 0.18) alone or combined (P ¼ 0.76) (Figure 1 ).
Compared to women in the third quintile of breast cancer allele sum, the age-and study-adjusted hazard ratio for breast cancer among women increased from 0.71 (95% confidence interval, 0.58-0.86) for women in the first quintile to 1.29 (1.09-1.52) for women in the fifth quintile (trend-test, P ¼ 1Â10 Age-and study-adjusted hazard ratio for breast cancer in women per breast cancer allele increase was 1.04 (1.03-1.05), with similar effect sizes across all strata of conventional breast cancer risk factors (Figure 3 ). After taking 12 tests into consideration, there was no evidence of interaction on incidence of breast cancer. Breast cancer allele sum was not associated with any individual cancer other than breast cancer (supplementary Figure S2 , available at Annals of Oncology online).
Breast cancer mortality
Age-and study-adjusted hazard ratio for breast cancer mortality in women per breast cancer allele increase was 1.05 (1.02-1.08), with similar effect sizes across all strata of conventional breast cancer risk factors; there was no indication of interaction on breast cancer mortality ( Figure 4 ).
Absolute risk of breast cancer
The lowest absolute 5-year breast cancer risk of 0.1% was in parous women, below age 40 years, without first degree relatives with breast cancer, in the first breast cancer allele sum quintile ( Figure 5 ). The highest risk of 7.7% was in nulliparous women, aged 70-74 years, with a first degree relative with breast cancer, in the fifth breast cancer allele sum quintile.
In Denmark and in many other countries, women aged 50-69 years are offered screening mammography. In 50-year-old women in this study, the average 5-year breast cancer risk was 1.5%, overall and 1.1%, 1.4%, 1.6%, 1.7%, 2.1%, for women in the first through fifth quintile, respectively (not shown). We used the 1.5% risk as a de facto cutoff risk for screening, when dichotomizing predictions of 5-year risk. Among women aged 50-54 and 55-59 years, 72% and 41% had absolute 5-year risks of breast cancer 1.5% ( Figure 5 ). Among women aged 50-69 years combined, 25% and 75% had risk 1.5% and >1.5%. Corresponding frequencies in women aged 40-49 years were 94% and 6%, and in women aged 69-79 years, 0% and 100%.
Sensitivity analyses
Polygenic risk score is the product of all risk alleles and their individual odds ratios reported in previous studies. For the analyses reported above results for the polygenic risk score and risk and mortality of breast cancer were slightly more pronounced than for allele sum; however, for the absolute 5-year risk chart, the change was negligible (supplementary Figure S3 , available at Annals of Oncology online). Analyses of interactions with conventional risk factors and for associations with other cancer types remained insignificant using polygenic risk score (data not shown). Figure 2 . Risk of breast cancer and other cancers according to quintiles of breast cancer allele sum. Cox proportional hazard ratios according to ranked quintiles of breast cancer allele sum for the risk of breast (women only) and other cancers (women and men combined). The hazard ratios were calculated using Cox regression models, adjusted for age (as time scale), and study population for risk of breast cancer, and additionally for sex for other cancers. Fifteen individuals had a first cancer other than breast cancer prior to their 20th birthday, and were excluded from the study of other cancers. HR, hazard ratio; CI, confidence interval.
Discussion
In this prospective analysis of >35 000 individuals from the Danish general population, each breast cancer risk allele was associated with a 4% increase of breast cancer incidence, and with 5% increased breast cancer mortality. In contrast, breast cancer alleles were not associated with incidence of other cancers. This is a novel finding. Of women aged 50-69 years, currently being offered screening mammography, 25% had an absolute 5-year risk below the cutoff risk, when calculating risk as a function of age, familial breast cancer, nulliparity, and quintiles of breast cancer allele sum. This finding suggests that measurement of breast cancer allele sum could be beneficial when counselling of women considering mammography, since estimates are based on a sample from the general population followed for many years.
Most of the 72 breast cancer susceptibility SNPs are in or near genes with roles in cell division, differentiation, apoptosis, DNA repair pathways, mammary gland development, or in estrogen receptor signaling pathway [9, 10] , but the exact mechanisms behind associations are largely unknown with the exception of a few Figure 3 . Risk of breast cancer by strata of risk factors, calculated as risk increase per breast cancer allele among 19 010 women from the Danish general population. Cox proportional hazard ratios estimated as risk increase per risk allele, stratified on age, alcohol consumption, nulliparity, hormone replacement therapy, physical activity, education level, income, body mass index, plasma C-reactive protein, familial breast cancer, study population, and follow-up time. Hazard ratios were adjusted for age (as time scale) and study population, except when examining study population with age only adjustment. Sum of individuals vary slightly due to incomplete information on a few individuals. *According to likelihood-ratio test. HR, hazard ratio; CI, confidence interval. † High consumption defined as > 84 g alcohol/week. ‡Only among postmenopausal women. §Not adjusted for study. NS: Not significant after adjusting for 12 multiple tests according to the Bonferroni method (required P¼0.05/12¼0.004). [11, 12] . It is also frequently unknown whether the SNP itself is causal, or in linkage disequilibrium with a nearby unidentified variant causally related to the observed risk [9, 13] . That said, these SNPs do provide risk stratification of women, as also demonstrated in the present study.
Prior to this study, it was plausible that at least a fraction of the 72 SNP loci could be associated with other cancer types than breast cancer, given the potential impact on cell processes shared by many cancers. However, our results support the notion that the breast cancer allele sum is not associated with risk of other cancers. This is important and reassuring if breast cancer allele sum is to be incorporated in a risk estimation tool in order to individualize screening interventions against breast cancer [14] ; the clinical interpretation and communication of the test result can be focused specifically on breast cancer risk. Furthermore, since the predictive information of breast cancer allele sum did not seem to depend upon other lifestyle risk factors beyond that of the expected simple multiplicative interaction [15] , the calculation of the individual woman's breast cancer risk could simply be done by multiplying relative risks from each risk factor.
Compared to a recent case-control study [6] , risk estimates in our study are generally congruent, but slightly less pronounced. We genotyped 72 instead of 77 SNPs, which produced a slightly narrower distribution of the breast cancer allele sum, and thus (presumably) a narrower risk distribution. Our use of the simple breast cancer allele sum instead of a polygenic risk score, i.e. the Figure 4 . Breast cancer mortality by strata of risk factors, calculated as risk increase per breast cancer allele among 19 010 women from the Danish general population. Cox proportional hazard ratios estimated risk increase per risk allele, stratified on age, alcohol consumption, nulliparity, hormone replacement therapy, physical activity, education level, income, body mass index, plasma C-reactive protein, familial breast cancer, and study population. Hazard ratios were adjusted for age (as time scale) and study population, except when examining study population with age only adjustment. Sum of individuals vary slightly due to incomplete information on a few individuals. *According to likelihood-ratio test. HR, hazard ratio; CI, confidence interval. †High consumption defined as > 84 g alcohol/week. ‡Only among postmenopausal women. §Not adjusted for study.
product of all risk alleles and their individual odds ratio reported in previous studies, represents a conservative approach, since it narrows the risk distribution compared with a polygenic risk score. However, it also makes our results robust against any future revisions of exact odds ratios. The estimate per breast cancer allele for breast cancer mortality was similar to that for breast cancer incidence in contrast to a recent prospective case-only study, where high polygenic risk score was associated with lower risk of metastasis [16] . Since that study did not report on mortality, our somewhat divergent findings are, however, not incompatible. Also, a recent meta-analysis did detect a nominal association between some of the common germline variants and survival outcomes [17] . This suggests that breast cancer allele sum captures incidence of breast cancers with possible impact on life-expectancy.
It could be argued that the average absolute 5-year risk of 1.5% for 50-year-old women is high compared with other countries. However, in NORDCAN [18] , the incidences for 50-to 54-yearold Danish women from 2010 to 2014 varied between 257 and 305 per 100 000 women, roughly translating into an average 5-year risk of 1.4%, and thus close to our estimate of 1.5% and among the highest in the world [19] . Furthermore, even though the 1.5% estimate in our population might be relatively high, our conclusions would still be of interest in other countries with screening mammography, since the cutoff of 1.5% is derived from the examined women. Had we performed the study on women with overall lower absolute risk levels, the cutoff risk would be similarly reduced, and thus the conclusions likely similar.
Some limitations to our study must be considered. First, we cannot exclude that individuals with many breast cancer risk alleles were less likely to participate than individuals with few risk alleles. The almost perfectly normal distributed breast cancer allele sum, and the Hardy-Weinberg equilibria across genotypes speak, however, against this. Second, we did not have access to information on mammography data, previous biopsy or history of previous benign breast disease, all main risk factors of breast cancer, and could therefore not include them in our analyses. Third, tumor characteristics from the 1301 breast cancers were not available, however, while interesting, such sensitivity analyses of estrogen-receptor or stage stratified risk was not the main focus, as we mainly wanted to examine risk assessment for breast cancer and other cancers in the general population. Fourth, the degree of reclassification above and below cutoff will depend both on the number of alleles included and the number of conventional risk factors used for risk assessment. Finally, as we studied Whites of Northern European descent only, our results may not necessarily apply to other ethnic groups [20] .
Strengths of this study include the large number of unselected individuals, including men, from the general population followed for many years without losses to follow-up, as well as the examination of any interactions between breast cancer allele sum and conventional breast cancer risk factors.
The future identification of additional risk loci as planed in the OncoArray consortium (http://epi.grants.cancer.gov/oncoarray/), as well as improved fine-mapping of known loci [21] , will widen the predicted risk distribution, and in turn increase the predictive value of the breast cancer allele sum. However, it is to be expected that the each of latest identified risk loci infer even smaller risk Figure 5 .
Absolute 5-year risk of breast cancer estimated from 18 381 women from the Danish general population. Absolute 5-year risk for breast cancer as estimated incidence rates (events per 5 years) in percentages for women according to age, familial history of breast cancer, nulliparity, and quintiles of breast cancer allele sum. Women with breast cancer before blood sampling were excluded from this analysis. Colors denote risk intensity as doublings of 1.5%, the average 5-year risk of a 50-year aged woman in this study. Columns at the right show the percentage of all women with absolute 5-year risks below or equal to and above 1.5%. The first two are for each age stratum, and the last two are according to current criteria for invitation to screening mammography in many countries.
changes than the loci included in this study. Therefore, we would not expect that our estimates would differ much, had we included those loci. This would presumably, however, have narrowed our confidence intervals. It remains important to validate theoretical benefits, and test potential unspecific associations of such a test in prospective studies of the general population. As we move closer toward precision medicine, the ability to incorporate genetic information into women's profiles, allows for more informed decisions based upon all available known risk factors. Such an approach must be implemented with care since it is possible that this information could create anxiety in women found to be at increased risk. Therefore, while not covered here, women's reaction to such information, and how they choose to utilize it, is an important topic, which has to be addressed before routine implementation.
Taken individually, each breast cancer risk allele association is too weak to be useful in a clinical setting. However, as a sum, in combination with age, familial breast cancer, and nulliparity, they can help to identify women with an absolute risk below the current risk cutoff compared with the strict age-only based criteria [5, 22] , and potentially to reduce the number of women who are offered screening mammography by almost one-fourth.
